NASDAQ · SABS
SAB Biotherapeutics, Inc.
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
Loading market information…
NASDAQ · VRCA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Verrica Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Verrica Pharmaceuticals Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.45. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Verrica Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$1.00+18.96% vs estimate | $3.44M+35.65% vs estimate |
|---|
| Q4 2024 | Mar 11, 2025 | -$2.40-650.0% vs estimate | $344.00K-66.97% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | -$4.90-32.43% vs estimate | -$1.78M-133.85% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $9.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
$2.48-$0.02 (-0.8%)
Boundless Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.62% below the high.
$5.34$0.00 (0.0%)
Generation Bio Co.’s quoted price sits in the upper half of its reported 52-week range, 28.95% below the high.
$2.04$0.00 (0.0%)
Mural Oncology plc’s quoted price sits in the lower half of its reported 52-week range, 56.96% below the high.
$6.53+$0.19 (+2.92%)
NextCure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.55% below the high.
$3.08-$0.03 (-0.96%)
Evaxion Biotech A/S’s quoted price sits in the lower half of its reported 52-week range, 55.49% below the high.
